-
1 Comment
Essex Bio-Technology Limited is currently in a long term uptrend where the price is trading 42.9% above its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
Essex Bio-Technology Limited's total revenue sank by 6.2% to $654M since the same quarter in the previous year.
Its net income has dropped by 1.8% to $170M since the same quarter in the previous year.
Finally, its free cash flow grew by 187.2% to $88M since the same quarter in the previous year.
Based on the above factors, Essex Bio-Technology Limited gets an overall score of 3/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | KYG312371035 |
| Market Cap | 2B |
|---|---|
| PE Ratio | 7.77 |
| Target Price | 6.84 |
| Beta | -0.11 |
| Dividend Yield | 2.9% |
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in the People's Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops, as well as Iodized lecithin capsules. It also provides healthtech e-platform-related medical services, Beifuji spray and lyophilized powder, and Beifuxin gels to treat surface wounds. The company offers Carisolv, a dental caries removal gel; mouthwash granules; oral care products; portable ultraviolet phototherapy devices; PELNACTM, a collagen-based artificial dermis; SCALGENTM, a double-layered artificial dermis; bioresorbable implants for dental surgery; hydrophilic contact lens; foldable capsular vitreous body and other medical devices for myopia control and prevention; eye-protection lamp; and defocus customized glasses. It develops SkQ1 eye drop, which is in the second phase 2 clinical trial; Azithromycin eye drops; Bevacizumab intravitreal injection for wet-AMD, which is in phase 3 clinical trial; and Cyclosporine eye drop, which is in phase 2 clinical trial, as well as new therapeutics in oncology, orthopedics, and neurology. It has license agreements with Mitotech S.A. and Mitotech LLC for a clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended to treat macular degeneration. The company was founded in 1990 and is headquartered in Zhuhai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1061.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
